Ruxolitinib cream for skin graft-versus-host disease
Part of Immune system & allergy, Skin clinical trials.
This study tests a cream called ruxolitinib on the skin rash caused by graft-versus-host disease (GVHD) after a bone marrow or stem cell transplant. The goal is to see if the cream safely reduces the rash without needing stronger medicines by mouth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 2 and 35 years old.
- You must have acute skin GVHD (a rash that happens after a transplant when donor cells attack your skin).
- You must have been diagnosed with cancer (malignancy) that led to the transplant.
- You cannot be on other medicines to treat acute GVHD by mouth or through a vein (except certain preventive ones).
- If you used steroid creams or tacrolimus cream on your skin, you must stop them 24 hours before starting the study.
- You must not have an active skin infection, allergies to ruxolitinib, or have used investigational drugs in the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called ruxolitinib for treating acute graft-versus-host disease (aGVHD), a common complication after a stem cell transplant. It may help control the immune reaction without using high doses of steroids.
This study looks at how well a medicine called ruxolitinib works for patients with graft-versus-host disease (GVHD)—a condition where donor cells attack your body after a bone marrow or stem cell transplant. The trial aims to understand if ruxolitinib can help control this side effect.
This trial tests whether adding ruxolitinib to standard steroid treatment works better than steroids alone for people with moderate to severe chronic graft-versus-host disease (cGVHD). cGVHD is a condition where donor immune cells attack the body after a stem cell transplant.
This trial tests whether the drug ruxolitinib, given based on a blood test that predicts risk, can prevent chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It may help people who have a higher risk of developing this complication.
This trial tests whether the drug ruxolitinib, given before and after a stem cell transplant, can help prevent graft-versus-host disease (GVHD) in people with blood cancers. GVHD is a common complication where donor cells attack the patient's body.
This trial tests a cream called ruxolitinib for adults with vitiligo on the face and neck that has not responded well to another cream (tacrolimus). The goal is to see if this cream can help bring back skin color.
Hear when a new Acute Skin Graft Versus Host Disease (GVHD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.